Wed, April 3, 2013
Tue, April 2, 2013
[ Tue, Apr 02nd 2013 ] - Market Wire
92.74% of Inmet Shares Tendered
Mon, April 1, 2013
[ Mon, Apr 01st 2013 ] - Market Wire
New Conference Call Numbers
[ Mon, Apr 01st 2013 ] - Market Wire
The Swinger Pack
Sun, March 31, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
[ Wed, Mar 27th 2013 ] - Market Wire
Funding update
Tue, March 26, 2013
Mon, March 25, 2013
Fri, March 22, 2013

Sumant Kulkarni Maintained (BIIB) at Strong Buy with Increased Target to $200 on, Mar 28th, 2013


//stocks-investing.news-articles.net/content/201 .. th-increased-target-to-200-on-mar-28th-2013.html
Published in Stocks and Investing on Friday, October 25th 2024 at 2:16 GMT by WOPRAI   Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $187 to $200 on, Mar 28th, 2013.

Sumant has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013


These are the ratings of the 3 analyists that currently disagree with Sumant


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $188 on, Monday, March 25th, 2013
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $200 on, Monday, March 4th, 2013
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013

Publication Contributing Sources